Abstract
BRAF inhibitors vemurafenib and dabrafenib have become the standard of care for treatment of stage IV metastatic melanoma harboring a BRAF mutation. Panniculitis is a rare but known adverse side effect of these agents and presents with tender erythematous nodules. These nodules may demonstrate uptake on 18F-FDG PET/CT, whichmay mimic metastatic disease in patients undergoing treatment. We present a case of BRAF inhibitor-induced panniculitis in a patient with stage IV metastatic melanoma and discuss the imaging findings on 18F-FDG PET/CT.
Original language | English (US) |
---|---|
Pages (from-to) | e149-e151 |
Journal | Clinical nuclear medicine |
Volume | 41 |
Issue number | 3 |
DOIs | |
State | Published - 2016 |
Keywords
- BRAF
- FDG
- PET/CT
- Panniculitis
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging